Physician
Oncology
Dr. Manuel Modiano, MD
|
|
Give Review
Manuel Modiano works in the field of Oncology. He has 7 awards "Past President", "Certificate of Merit", "Outstanding Fellow", "Chief Resident", "Outstanding Senior Resident", "Outstanding Medical Resident" and "Meaningful Use Stage 1 Certification". Manuel Modiano is a published doctor. He has 43 publications published. The most current publication "Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)." He is registered with Medicare.
Publications
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracyclin...
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in ...
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non...
- Predictors of cervical Cancer screening in Mexican American women of reproductive age.
- CT findings after hepatic chemoembolization.
- North American Conference on Cancer in Hispanics.
- A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.
- Breast and cervical Cancer in Hispanic women.
- Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast Cancer and melanoma.
- Ocular toxic effects of fenretinide.
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas Cancer: a randomized trial.
- Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of Acute emesis after moderately emetogenic chemotherapy. Oral Do...
- Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
- Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
- Cancer in Hispanics: issues of concern.
- A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanc...
- Mitoxantrone and fludarabine in the Treatment of patients with non-Hodgkin''s lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
- Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast Cancer.
- A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenoCarcinoma: a Southwest Oncology Group study (...
- Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic coloRectal carcinoma: A Southwest Oncolog...
- Phase I study of adozelesin (U-73,975) in patients with solid Tumors.
- Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous Carcinoma of the cervix.
- Markedly decreased coronary Blood flow in secondary polycythemia.
- Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in Cancer patients.
- Use of breast Cancer screening by older Hispanic women.
- A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin''s lymphoma.
- Phase II evaluation of topotecan in patients with advanced colorectal Cancer. A Southwest Oncology Group trial (SWOG 9241).
- ZD0473 treatment in lung Cancer: an overview of the clinical trial results.
- An educational program to increase cervical and breast Cancer screening in Hispanic women: a Southwest Oncology Group study.
- Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian Cancer.
- Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 stud...
- Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adju...
- A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic Cancer.
- Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
- Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic Cancer.
- Phase I trial of imexon in patients with advanced malignancy.
- Adjuvant docetaxel for node-positive breast Cancer.
- A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic Cancer.
- A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cel...
- Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reDuctase inhibitor, administered daily for five days in patients with advanced solid tumors.
- Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate Cancer.
- Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.
Schools
Universidad Nacional Autonoma De Mexico
Sinai Samaritan Medical Center
Sinai Samaritan Med Center
Arizona Cancer CenterUniv Of Arizona
Procedures Preformed
- Bone Marrow Aspiration
- Breast Cancer Treatment
- Cancer Treatment
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Past President
- Certificate of Merit
- Outstanding Fellow
- Chief Resident
- Outstanding Senior Resident
- Outstanding Medical Resident
- Meaningful Use Stage 1 Certification
Education
-
University of Arizona -
Universidad Nacional Autonoma de Mexico
Drug Facts
| NPI NUMBER | 1003864380 | |
| NPPES Provider LastName | MODIANO | |
| NPPES Provider FirstName | MANUEL | |
| NPPES Provider ZIPCode | 857452624 | |
| NPPES Provider State | AZ | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1246.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 56.0 | |
| Percent Opioid Claims | 4.49 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003864380 |
| Last Name Of The Provider | MODIANO |
| First Name Of The Provider | MANUEL |
| View All |
Similar Doctors
|
Dr. Parminder Singh, MD |
|
|
Dr. Pavani Chalasani, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Boxer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leona B. Downey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tenney B. Kentro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tomislav Dragovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah G. McGinn, MD |
|
|
Dr. Morris H. Fine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pavani Chalasani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan M. Hersh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Shahram Mori, MD
This Doctor is OpenDoctor Recommended.
|